Breast Cancer Research Updates

Dear Colleagues, The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 This List Curated by: #OncoAlertAF Leads : @ElisaAgostinett 🇧🇪 @to_be_elizabeth 🇮🇹 @weoncologists 🇺🇸 With our distinguished OncoAlert Faculty: @ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @E_de_Azambuja 🇧🇪 @hoperugo 🇺🇸 @stolaney1 🇮🇹 @matteolambe 🇮🇹 and @JaniceTNBCmets 🇮🇹 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy : Primary results from DESTINY-Breast06 (DB-06). meetings.asco.org/abstracts-pres… Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202. meetings.asco.org/abstracts-pres… DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. meetings.asco.org/abstracts-pres… Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial meetings.asco.org/abstracts-pres… Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL meetings.asco.org/abstracts-pres… SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. meetings.asco.org/abstracts-pres… A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. meetings.asco.org/abstracts-pres… Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial. meetings.asco.org/abstracts-pres… Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. meetings.asco.org/abstracts-pres… On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3). meetings.asco.org/abstracts-pres… @aftimosp @NicoleKuderer @FAndreMD @prat_aleix @jesusanampa @StoverLab @curijoey @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @raalbany @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @paspears88 @MammaMiaMagazin #OncoAlertAF @nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1 @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @dr_yakupergun @anmwongNZ

#ESMOBreast24: What do you find the most relevant #ScientificAdvancements in #OncologyResearch? Share the newest findings that you consider having the potential to improve #CancerCare in #bcsm. #BreastCancer #ESMOAmbassadors

Great news‼️🚨 Updates to germline testing in #breastcancer patients from @ASCO and the Society of Surgical Oncology emphasize the paramount importance of BRCA1/2 mutation testing in newly diagnosed breast cancer patients, especially those ≤65 years of age, and in patients over 65 years of age, taking into account their personal history, relatives, ancestry, and eligibility for poly(ADP-ribose) polymerase inhibitor (PARP) therapy. Recommendations: 🔵All newly diagnosed breast cancer patients ≤65 years of age should undergo BRCA1/2 mutation testing. 🟣Selected patients over 65 years of age should be evaluated based on history, ancestry, and eligibility for PARP therapy. 🟡Patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should undergo the BRCA1/2 test, regardless of family history. 🟠Women with second primary cancer in the ipsilateral or contralateral breast should undergo BRCA1/2 testing. 🟢Patients with a history of breast cancer, without active disease, should be evaluated, selectively, according to age of diagnosis and personal and family risk. 🌟Expansion of testing to high-penetrance cancer susceptibility genes beyond BRCA1/2 is also recommended, especially in those with a supportive family history. Where necessary, moderate-penetrance gene testing may be offered to assess personal and family cancer risk, this comprehensive approach makes a huge difference in personalizing breast cancer therapy and prevention.🙌🏻 @OncoReporte @oncosurgeonjd @Dr_RShatsky @ProfAMThompson ascopubs.org/doi/full/10.12…

Excited to share this paper that discusses priorities to reducing race disparities in breast cancer. Grateful to @maretmaliniak and @LMoubadder for their support of this idea and contributions to the content. @WinshipAtEmory @EmoryRollins jamanetwork.com/journals/jamao…

TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo 63% w/1L prior chemo ~80% w/prior cdk 4/6i PFS 6.9 vs 4.9 mo, HR 0.63, p<0.0001 ORR 36.4% vs 22.9% Fewer grade >=3 AEs w/Dato-DXd c/w TPC 50% Stomatitis,3% ILD @OncoAlert #bcsm #ESMO23 @dradityabardia

Another study showing metformin doesn't have the effect on improving risk or outcome for #bcsm that we hoped it might. @ASCO #MA32 ascopost.com/news/september…

Expect a great discussion and update on HR+ breast cancer 🧬🧬 @matteolambe @dr_yakupergun @ErikaHamilton9 @quirogad @BreastCaupdates @oncodaily @BreastAdvocate @Erman_Akkus